Af­fimed nar­rows PhI/IIa fo­cus; Bris­tol My­ers pays Agenus $25M; Mer­ck, Mod­er­na start an­oth­er PhI­II can­cer vac­cine

Plus, news on No­var­tis’ re­cent­ly-ap­proved ip­ta­co­pan and Acurx’s an­tibi­ot­ic.

Af­fimed drops some in­di­ca­tions from PhI/IIa tri­al: As the biotech re­ports promis­ing mid-stage da­ta for its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER